Castle Biosciences stock gained 3.07 percent before lab opening
Published on 10/06/2026 at 12:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Castle Biosciences (ISIN US14843C1053) stock was last at USD 36.65 on Nasdaq on October 5, 2026 at 4:00 p.m. ET, up 3.07 percent. The company scheduled the opening of its new Scottsdale laboratory and office facility for October 6, 2026, at 3:30 p.m. Mountain Standard Time, according to Castle Biosciences in its September 22, 2026 release.
A 55,000-square-foot capacity bet
The Scottsdale site adds 55,000 square feet in the Phoenix metropolitan area and is designed to support growing laboratory test volumes. The facility sits in the 260-acre Perimeter Center business park and includes upgraded HVAC, information technology and security infrastructure, plus backup power systems, Castle Biosciences said on September 22, 2026.
As of June 30, 2026, Castle employed more than 1,000 people across the United States, including approximately 220 in the greater Phoenix area. That staffing footprint gives the facility announcement an operating dimension beyond a property expansion.
Q2 revenue beat the estimate
Castle reported Q2 2026 revenue of USD 103.55 million and a net loss of USD 2.06 million, with the period ending June 30, 2026, according to Yahoo Finance. The revenue figure exceeded the USD 86.23 million analyst estimate cited by MarketBeat for the same quarter.
The operating picture is therefore mixed in a precise way: revenue is expanding faster than the cited forecast, while the company still posts a quarterly loss. For investors, the new lab increases capacity, but the next test is whether that capacity converts into sustained earnings improvement.
Stock stays below its yearly high
CSTL was last at USD 36.65 on Nasdaq on October 5, 2026 at 4:00 p.m. ET, with a market capitalization of USD 1.1 billion; the 52-week range was USD 17.72 to USD 44.28. The last price stood 17.23 percent below the yearly high.
Stock Analysis reported on October 1, 2026 that nine analysts held a Strong Buy consensus, with an average price target of USD 45.11, a low of USD 35 and a high of USD 57. The average target lies 23.08 percent above the October 5 price, leaving the market focused on execution after the facility opening.
Castle Biosciences stock details
- Company: Castle Biosciences, Inc.
- ISIN: US14843C1053
- Ticker: CSTL
- Trading venue: Nasdaq
- Price (as of October 5, 2026, 4:00 p.m. ET): USD 36.65
- Market capitalization: USD 1.1 billion (as of October 5, 2026)
- 52-week range: USD 17.72-44.28 (as of October 5, 2026)
- Sector / Industry: Healthcare / Medical Equipment, Supplies and Distribution
